Presentations and Posters
14 November 2011
The herapen sulfate mimetic PG545, as a monotherapy or in combination with standard-of-care agents paclitaxel or carboplatin, significantly inhibits solid tumor progession in two murine models of ovarian cancer
Keith Dredge, Edward Hammond, Paul Handley, Jessica Rowley, Melissa Peart, Ralf Brandt & Ian Bytheway. Progen Pharmaceuticals Ltd, Darra, Brisbane, Queensland, 4076, Australia. Vivopharm Pty Ltd, 1-5 Wakefield St, Kent Town, South Australia, 5067, Australia. .
Click here for poster
11 February 2011
The PreClinical Development of PG545 , A New Heparan Sulfate Mimetic With The Potential To Simultaneously Block Tumour Angiogenesis And Metastatis
Keith Dredge, Edward Hammond, Christina Vincent, Ralf Brandt, Thomas Gonda, Maree Smith & Ian Bytheway. Progen Pharmaceuticals Ltd, Brisbane, Queensland, Australia.
Vivopharm Pty Ltd, Adelaide, South Australia, Australia. Molecular Oncogenesis Group, Diamantina Institute, University Of Queensland, Brisbane, Australia. Centre For Intergrated Preclinical Drug Development, University of Queensland, Brisbane, Australia.
Click here for poster
2 February 2010
The Dual Angiogenesis/Heparanase Inhibitor PG545 Supresses Metastasis in Models of Melanoma, Breast and Lung Cancer - An Advantage Over Tyrosine Kinase Inhibitors?
Keith Dredge, Edward Hammond, Paul Handley, Thomas J Gonda, Ian Bytheway. Progen Pharmaceuticals Ltd, Brisbane, Australia; Diamantina Institute of Cancer, Immunology and Molecular Medicine, University of Queensland, Brisbane, QLD, Australia.
Click here for poster
16 November 2009
New Preclinical Data confirms PG545 as a promising clinical candidate for cancer: Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
Ian Bytheway, Edward Hammond, Paul Handley, Keith Dredge. Progen Pharmaceuticals, Brisbane, Qld, Australia.
Click here for poster 1
Edward Hammond, Ian Bytheway, Paul Handley, Michelle Kappler, Crystal McGirr, Thomas J Gonda, Maree Smith, Keith Dredge. Progen Pharmaceuticals, Brisbane, Qld, Australia; Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland; Centre for Integrated Preclinical Drug Development, St Lucia Campus, University of Queensland, Brisbane, Australia.
Click here for poster 2
20 April 2009
Update on Epigenetics Platform with Full list of Abstracts
Click here for announcement
14 April 2008
PG500 Series Presented at the AACR Annual Meeting in San Diego
Anand Gautam, Keith Dredge, Ligong Liu, Cai Ping Li, Ken Johnstone, Edward Hammond, Norbert Wimmer, Ian Bytheway, Tom Gonda, Vito Ferro. Drug Design Group, Progen Pharmaceuticals, Brisbane, Qld, Australia; Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland.
Click here for poster
4 February 2008
Progen Expands Drug Development Pipeline Through Aquisition of CellGate, Inc.
Click here for presentation
23 October 2007
Progen Presents Preclinical Data for Second-Generation Anti-Tumor Compounds at AACR-NCI-EORTC International Conference
Dredge K, Davies K, Liu L, Handley P, Wimmer N, Bytheway I, Hammond E, Li CP, Rowley J, Ferro V, Gautam A. Drug Design Group, Progen Pharmaceuticals, Brisbane, Qld, Australia
Click here for poster